FLUSIN SINUS SYRUP
(and dosage form)
FLUSIN SINUS SYRUP
Each 5 mL contains:
Triprolidine hydrochloride monohydrate 1,25 mg
Pseudoephedrine hydrochloride 30,00 mg
Methyl hydroxybenzoate 0,12% m/v
Propyl hydroxybenzoate 0,02% m/v
A 5.8 Preparations for the common cold including decongestants and antihistaminics.
FLUSIN SINUS SYRUP has antihistaminic and decongestant properties.
The symptomatic relief of mucosal congestion of the upper respiratory tract associated with colds and influenza.
Hypersensitivity to any of the ingredients.
FLUSIN SINUS SYRUP should not be administered to patients suffering from cardiovascular disease (especially coronary insufficiency), hypertension, prostatism thyrotoxicosis, bladder dysfunction, closed angle glaucoma, phaeochromocytoma and during an attack of asthma in asthmatic patients.
Patients being treated with monoamine oxidase inhibitors and within two weeks of stopping such treatment, ephedrine and other sympathomimetic agents as a hypertensive response may result.
Safety in pregnancy and lactation has not been established.
FLUSIN SINUS SYRUP is contra-indicated in children under two years of age.
FLUSIN SINUS SYRUP may lead to drowsiness and impaired concentration, which may be aggravated by the simultaneous intake of alcohol or other central nervous system depressant agents. Patients should not drive, climb dangerous heights or operate machinery as impaired decision-making could lead to accidents.
Pseudoephedrine should be given with caution to patients with organic heart disease, cardiac decompensation or angina of effort and in patients receiving digitalis.
Do not use this product without consulting a doctor or pharmacist if you are presently taking monoamine oxidase inhibitors or other medicines for depression, psychiatric or emotional conditions or hypertension.
DOSAGE AND DIRECTIONS FOR USE:
Adults and children over 12 years: 5-10 mL.
Children 6 - 12 years: 5 mL
Children 2 - 6 years: 2,5 mL
May be given three times daily
Not recommended for children under 2 years of age.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
The side-effects of triprolidine include sedation varying from drowsiness to deep sleep, and including lassitude, dizziness and inco-ordination.
Paradoxical stimulation may occur particularly in children, with insomnia, nervousness, euphoria, irritability, tremors, and rarely, nightmares, hallucinations and convulsions.
Other effects include dry mouth, thickened respiratory tract secretions and tightness of the chest, blurred vision, urinary difficulty and retention, a reduction in tone and motility of the gastro-intestinal tract resulting in constipation and increased gastric reflux, in high doses, transient bradycardia followed by tachycardia with palpitations and arrhythmias; hypotension, tinnitus, headaches and paraesthesias.
Other gastro-intestinal disturbances include nausea, vomiting, diarrhoea and epigastric pain.
Blood disorders include agranulocytosis, leucopenia, haemolytic anaemia and thrombocytopenia.
Central effects include fear, anxiety, restlessness, tremor, insomnia, confusion, irritability and psychotic states. Appetite may be reduced, and nausea and vomiting may occur.
Cardiovascular effects include hypertension which may produce cerebral haemorrhage and pulmonary oedema and reflex bradycardia.
Tachycardia, cardiac arrhythmias, angina pain, palpitations, cardiac arrest, and hypotension with dizziness and fainting, and flushing may also occur.
Other side-effects include: difficulty in micturition and urinary retention, dyspnoea, weakness, altered metabolism including disturbances of glucose metabolism, sweating and hypersalivation, and headache.
Should not be given to premature infants or neonates.
Should be used with care in the elderly who are more susceptible to many of the side-effects, patients with closed angle glaucoma, urinary retention, prostatic hypertrophy or pyloro-duodenal obstruction, epilepsy, severe cardiovascular disorders.
Should not drive or operate machinery.
Should avoid alcoholic drinks.
Special care should be taken in patients with hyperthyroidism, cardiovascular disease such as ischaemic heart disease, arrhythmia or tachycardia, occlusive vascular disorders including arteriosclerosis, hypertension and aneurysms. Anginal pain may be precipitated in patients with angina pectoris.
Diabetes mellitus and closed-angle glaucoma.
Pseudoephedrine should be avoided or used with caution in patients undergoing anaesthesia with cyclopropane, halothane or other halogenated anaesthetics, as they may induce ventricular fibrillation.
An increased risk of arrhythmias also occurs if given with cardiac glycosides, quinidine or tricyclic antidepressants.
Interaction with monoamine oxidase inhibitors and should not be given to patients receiving such treatment or within 14 days of its termination.
Pseudoephedrine increases blood pressure and therefore special care is advised in patients receiving antihypertensive therapy.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Overdosage may be fatal especially in infants and children. In infants and children, CNS excitement predominates with ataxia, excitement, tremors, psychoses, hallucinations and convulsions; hyperpyrexia may also occur. Deepening coma and respiratory collapse may follow.
In adults, CNS depression is more common with drowsiness, coma and convulsions, progressing to respiratory failure and possibly cardiovascular collapse.
The stomach should be emptied. Emetics may be tried if the patient is alert and there is no symptoms of toxicity.
Other treatment should be symptomatic and supportive and may include artificial respiration, external cooling and IV fluids.
A light yellow clear syrupy solution with liquorice odour and taste.
Amber glass bottle containing 100 mL.
Store below 25ºC and protect from light.
KEEP OUT OF REACH OF CHILDREN.
NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
13 November 1995
Harrys Printers K
New addition to this site: May 2014
Source: Pharmaceutical Industry - Launched June 2011
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
Information presented by Malahyde Information Systems © Copyright 1996-2014